Evidence map›Paper›PMID 28429751›Full record

ArticleCancer gene therapy2017

Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals.

Q Ru, W Li, X Wang, S Zhang, L Chen, Y Zhang, Y Ge, Y Zu, Y Liu, D Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Q RuInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China.
W LiNational Institutes for Food and Drug Control, National Center for Safety Evaluation of Drugs, Beijing, China.
X WangNational Institutes for Food and Drug Control, National Center for Safety Evaluation of Drugs, Beijing, China.
S ZhangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, China.
L ChenInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China.
Y ZhangInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China.
Y GeInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China.
Y ZuObio Technology (Shanghai) Corp. Ltd, Shanghai, China.
Y LiuInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China.
D ZhengInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recombinant sTRAIL has been in clinical trial for various human malignancies. However, the half-life time of sTRAIL is very short, which might be an important factor influencing its clinical efficacy for cancer therapy. We previously reported the recombinant adeno-associated virus (AAV)-encoding sTRAIL

Indexed as

AnimalsDependovirusDisease Models, AnimalGene Expression Regulation, NeoplasticGenetic TherapyGenetic VectorsHumansMacaca fascicularisNeoplasmsRecombinant ProteinsTissue DistributionTNF-Related Apoptosis-Inducing LigandRecombinant ProteinsTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, human

Identifiers

PMID28429751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.